There is evidence that Her2+ breast cancer (BC) cell lines resistant to trastuzumab show amplification and overexpression of cyclin E. These lines are more sensitive to inhibition of CDK2/9 by fadraciclib, which caused both cell cycle arrest and apoptosis [25]. Here, ERBB2 is linked to breast cancer.